Alkem Laboratories and Johns Hopkins University (JHU) have entered into an exclusive license agreement for the development and commercialization of JHU's novel target and technology that will help patients with colorectal cancer. This technology, a novel target, will serve as a bona fide biomarker and antagonist in human colorectal cancer based on angiogenesis and inflammation.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
